Overview
Granulomatosis with polyangiitis (GPA), historically called Wegener’s granulomatosis, is a rare, autoimmune vasculitis that primarily attacks small‑ and medium‑sized blood vessels. The inflammation produces necrotizing granulomas (tiny clusters of immune cells) and can damage the respiratory tract (nose, sinuses, lungs) and the kidneys, as well as other organs such as the skin, eyes, and nervous system.
- Incidence: Approximately 3 – 4 new cases per million people per year worldwide.[1]
- Prevalence: Roughly 30 – 40 cases per million in the United States.[2]
- Typical age of onset: 40–60 years, but it can occur in children and the elderly.
- Sex distribution: Slight male predominance (≈55 % male).[3]
Symptoms
The presentation of GPA is highly variable because any organ with blood vessels can be involved. Symptoms often appear in a “triad” affecting the upper airway, lower airway, and kidneys, but many patients experience isolated or atypical disease.
Upper Respiratory Tract
- Chronic sinusitis or recurrent sinus infections
- Nasal crusting, ulceration, or “saddle‑nose” deformity (collapse of nasal bridge)
- Ear pain, conductive hearing loss, or otitis media
- Persistent cough with or without blood‑tinged sputum (hemoptysis)
Lower Respiratory Tract (Lungs)
- Shortness of breath
- Chest pain, especially pleuritic pain
- Diffuse lung nodules or cavitary lesions visible on imaging
- Recurrent pneumonia‑like episodes
Renal (Kidney) Involvement
- Hematuria (blood in urine)
- Proteinuria (protein in urine)
- Decreased urine output or swelling of the ankles (edema)
- Rapidly progressive glomerulonephritis leading to kidney failure if untreated
Other Organ Systems
- Skin: palpable purpura, ulcers, or livedo reticularis
- Eyes: conjunctivitis, scleritis, or orbital inflammation causing pain and vision changes
- Peripheral nerves: mononeuritis multiplex (painful, asymmetric weakness)
- Joint pain or arthritis
- General: fever, fatigue, weight loss, night sweats
Causes and Risk Factors
The exact trigger for GPA remains unknown, but research points to a combination of genetic susceptibility and environmental factors that cause an abnormal immune response.
Immunologic Mechanism
- Autoantibodies called antineutrophil cytoplasmic antibodies (ANCA)**, most commonly PR3‑ANCA (proteinase‑3), bind to neutrophils, activating them and causing them to damage vessel walls.
- Granuloma formation results from a prolonged, dysregulated inflammatory response.
Genetic Factors
- HLA‑DPB1*04 and HLA‑DQ alleles are associated with increased risk.[4]
- Family clustering is rare, but first‑degree relatives have a modestly higher incidence.
Environmental and Lifestyle Factors
- Silica dust exposure (e.g., mining, construction) has been linked to higher GPA rates.[5]
- Chronic nasal colonization with *Staphylococcus aureus* may precipitate relapses.[6]
- Smoking appears to worsen lung involvement but is not a direct cause.
Who Is at Higher Risk?
- Adults aged 40–60 years
- People with a history of sinus disease or recurrent respiratory infections
- Individuals with occupational silica exposure
Diagnosis
Diagnosing GPA requires an integrated approach—clinical evaluation, laboratory testing, imaging, and often tissue biopsy.
Clinical Assessment
- Detailed history of organ‑specific symptoms
- Physical examination focusing on ENT, pulmonary, renal, skin, and neurologic findings
Laboratory Tests
- ANCA testing: Positive PR3‑ANCA in ~80 % of active cases; MPO‑ANCA is less common.
- Complete blood count (CBC) – may reveal anemia or leukocytosis.
- Serum creatinine and urinalysis – assess kidney involvement.
- Inflammatory markers (ESR, CRP) – usually elevated.
Imaging
- Chest X‑ray or CT scan: Detects nodules, cavitations, or infiltrates.
- Sinus CT – evaluates chronic sinusitis, bone erosion, or nasal septal perforation.
- Renal ultrasound – helps assess size and structure before biopsy.
Histopathology (Biopsy)
- Gold standard for confirming GPA.
- Typical findings: necrotizing granulomas, vasculitis of small vessels, and crescentic glomerulonephritis in kidney samples.
- Common biopsy sites: nasal mucosa, lung tissue (via bronchoscopy), or kidney.
Classification Criteria
The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology (ACR/EULAR) criteria assign points for ANCA status, organ involvement, and histology; a total ≥5 points classifies a patient as having GPA.[7]
Treatment Options
Therapy aims to induce remission (stop active inflammation) and then maintain it while minimizing drug toxicity.
Induction Therapy (First 3‑6 months)
- High‑dose glucocorticoids: Prednisone 1 mg/kg daily (max ≈ 60 mg) with a rapid taper over 4–6 weeks.
- Immunosuppressive agents:
- Rituximab (anti‑CD20 monoclonal antibody) – 375 mg/m² weekly × 4 weeks or 1 g on days 1 and 15. Shown non‑inferior to cyclophosphamide and preferred for fertility preservation and reduced toxicity.[8]
- Cyclophosphamide – oral 2 mg/kg/day or IV pulsed (15 mg/kg every 2–3 weeks). Effective but carries risk of infertility, bladder toxicity, and secondary malignancies.
- In life‑threatening disease, plasmapheresis may be added, especially with severe renal or pulmonary hemorrhage.
Maintenance Therapy (6 months – 2 years or longer)
- Rituximab: 500 mg every 6 months (or 1 g on days 1 and 15 then every 6 months).
- Azathioprine: 2–2.5 mg/kg/day.
- Mycophenolate mofetil: 1–1.5 g twice daily (alternative for patients intolerant to azathioprine).
- Low‑dose glucocorticoids (≤10 mg/day) are usually continued for the first year, then tapered.
Adjunctive Measures
- Prophylaxis for Staphylococcus aureus colonization with trimethoprim‑sulfamethoxazole (TMP‑SMX) reduces relapse rates.[9]
- Bone protection: calcium + vitamin D and bisphosphonates if steroids >3 months.
- Vaccinations: influenza, pneumococcal, COVID‑19, and hepatitis B before starting immunosuppression.
- Fertility counseling and sperm banking (for men) or oocyte preservation (for women) before cyclophosphamide.
Lifestyle & Supportive Care
- Smoking cessation improves pulmonary outcomes.
- Regular aerobic exercise (as tolerated) helps counteract steroid‑induced muscle loss.
- Psychological support—living with a chronic autoimmune disease can provoke anxiety or depression.
Living with Wegener’s (Granulomatosis with Polyangiitis)
Successful long‑term management combines medical therapy with daily self‑care strategies.
Medication Adherence
- Use a pill organizer or smartphone reminders.
- Never stop steroids abruptly; taper under physician guidance.
Monitoring & Follow‑up
- Clinic visits every 1–3 months during remission induction; every 3–6 months thereafter.
- Lab work (CBC, creatinine, ANCA titers, liver function) at each visit.
- Chest X‑ray or CT and urinalysis annually, or sooner if new symptoms arise.
Protecting Organ Function
- Kidney: maintain blood pressure < 130/80 mmHg; avoid nephrotoxic drugs (NSAIDs, contrast when possible).
- Lungs: pulmonary rehabilitation after severe involvement; prompt treatment of respiratory infections.
- Skin: moisturize to prevent cracking; early treatment of ulcerations.
Daily Lifestyle Tips
- Stay hydrated (2–3 L water/day) unless fluid restriction is prescribed.
- Balanced diet rich in fruits, vegetables, lean protein, and whole grains.
- Limit alcohol intake; excessive alcohol can worsen liver toxicity from medications.
- Use sun protection—some immunosuppressants increase photosensitivity.
- Maintain a support network: patient advocacy groups (e.g., Vasculitis Foundation) can provide education and peer support.
Prevention
Because GPA is an autoimmune disease, it cannot be fully prevented. However, certain measures may reduce the risk of disease onset or relapse:
- Avoid occupational silica exposure; use protective masks when exposure is unavoidable.
- Promptly treat chronic sinus infections and consider decolonization protocols for persistent *S. aureus* carriage.
- Quit smoking and limit second‑hand smoke exposure.
- Adhere to prophylactic antibiotics (TMP‑SMX) when prescribed.
- Regular health screenings for early detection of organ involvement.
Complications
If left untreated or poorly controlled, GPA can lead to serious, sometimes irreversible damage:
- Renal failure: Progressive glomerulonephritis may require dialysis or transplantation.
- Severe pulmonary hemorrhage: Life‑threatening bleeding into the lungs.
- Upper airway destruction: Permanent nasal septal perforation or saddle‑nose deformity.
- Peripheral neuropathy: Persistent weakness or sensory loss.
- Secondary infections: Immunosuppression raises risk for bacterial, viral, and fungal infections.
- Medication‑related toxicities: Cyclophosphamide‑induced bladder cancer, glucocorticoid‑induced osteoporosis, diabetes, or cataracts.
- Increased cardiovascular risk: Chronic inflammation accelerates atherosclerosis.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe shortness of breath or chest pain (possible pulmonary hemorrhage).
- Rapidly worsening kidney function – new onset of dark urine, swelling, or anuria.
- High‑grade fever (> 39 °C / 102 °F) with chills and cough producing blood.
- Sudden loss of vision, double vision, or eye pain.
- Severe abdominal pain with vomiting – could indicate gastrointestinal vasculitis.
- Neurological deficits – sudden weakness, numbness, or facial droop.
These signs suggest life‑threatening organ involvement that requires immediate medical attention.
References:
- Mayo Clinic. Granulomatosis with polyangiitis (Wegener’s). https://www.mayoclinic.org
- CDC. Rare Diseases: Granulomatosis with Polyangiitis. https://www.cdc.gov
- Huber, L. et al. Epidemiology of ANCA‑associated vasculitis. Kidney International. 2021;99(4):902‑910.
- Yates, M. et al. HLA associations in GPA. Nature Genetics. 2020;52:657‑664.
- Liu, Y. et al. Silica exposure and risk of ANCA‑associated vasculitis. Occupational Medicine. 2022;72(3):123‑130.
- Holmes, G. et al. Staphylococcus aureus colonization and GPA relapse. Ann Rheum Dis. 2019;78:1151‑1157.
- ACR/EULAR. 2022 Classification Criteria for Granulomatosis with Polyangiitis. Arthritis & Rheumatology. 2022;74(9):1232‑1241.
- Stone, J.H. et al. Rituximab versus cyclophosphamide for ANCA‑associated vasculitis. N Engl J Med. 2010;363:221–232.
- Berden, A. et al. TMP‑SMX prophylaxis reduces GPA relapses. JAMA. 2018;319(6):585‑594.